Clinical Trial Update: TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA. [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating safety, tolerability, and plasma pharmacokinetics of multiple doses of the long-acting rilpivirine formulation TMC278LA in HIV-1, whi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TMC278LA (rilpivirine long-acting formulation)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV-1 | Phase 1 | Status: TERMINATED